A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
- Indications Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Exelixis
- 12 Jun 2017 Status changed from not yet recruiting to recruiting according to an Exelixis media release.
- 30 May 2017 Status changed from planning to not yet recruiting.
- 03 Mar 2017 New trial record